查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994268

生物成像试剂市场：按产品类型、成像方式、最终用户和应用分類的全球市场预测，2026-2032年

Biologic Imaging Reagents Market by Product Type, Imaging Modality, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物成像试剂市场价值将达到 167.3 亿美元，到 2026 年将成长至 180.9 亿美元，到 2032 年将达到 309.8 亿美元，复合年增长率为 9.19%。

主要市场统计数据
基准年 2025 167.3亿美元
预计年份：2026年 180.9亿美元
预测年份 2032 309.8亿美元
复合年增长率 (%) 9.19%

全面介绍生物成像试剂及其在现代诊断和转化研究中在学术和临床环境中的关键作用。

生物成像试剂是现代诊断、临床前研究和转化科学的重要基础。这些试剂包括用于电脑断层扫描 (CT) 和磁振造影(MRI) 的造影剂、用于可视化分子过程的萤光标记物和发光探针，以及提供精确光学讯号的量子点。它们共同支持广泛的应用，从体外检测开发和离体组织表征到体内诊断成像和治疗监测，为研究人员、临床医生和工业开发人员提供了同等重要的支持。

分析了由技术融合、监管演变和新的转化应用所驱动的，正在重塑生物成像试剂领域的变革性变化。

生物成像试剂领域正经历一场变革性的转变，这场变革是由技术、监管和转化应用需求三者相互作用所驱动的。在技​​术层面，奈米材料、蛋白质工程和探针化学的进步使得试剂能够拥有更高的信噪比、更强的标靶特异性和更佳的生物稳定性。这些优势正在加速复杂成像模式的应用，并开启治疗监测和精准诊断等领域的新应用。

评估美国新关税政策对生物成像试剂供应链、筹资策略和市场进入的累积影响。

美国2025年实施的新关税政策将产生一系列累积效应，波及生物成像试剂的采购、生产和整体筹资策略。许多试剂依赖稀有元素、专有染料和奈米颗粒前体等特殊原料，而这些原料通常来自海外。因此，关税带来的成本压力促使企业重新评估其供应商组合，增加库存缓衝，并考虑进行策略性垂直整合，以减轻跨境价格波动的影响。

针对影响创新和采购决策的产品类型、影像方式、最终用户和应用途径进行详细的細項分析。

对细分市场趋势的多方面理解是生物成像试剂领域策略决策的核心。按产品类型划分，该生态系统包括造影剂、萤光标记物、发光探针和量子点。在造影剂中，微气泡、顺磁性造影剂和超顺磁性氧化铁分别满足特定的成像方式需求；萤光标记物涵盖萤光蛋白、奈米颗粒和有机染料；发光探针分为生物发光和化学冷光两种类型；量子点则分为碳基和硒化镉基两种系统。每个产品系列都有其独特的研发路径、监管考量和适用性，这些都会影响研发重点和市场定位。

美洲、欧洲、中东、非洲和亚太地区的区域趋势和战略意义，推动了当地的招募和投资重点。

区域趋势影响生物成像试剂的需求模式和策略重点。在美洲，完善的临床研究基础设施、成熟的生物技术丛集以及对转化科学的大量投资，推动了对先进试剂的需求，这些试剂能够支持临床试验和诊断技术的创新。监管可追溯性和长期的供应商关係在该地区采购週期中至关重要，各机构通常寻求能够实现从临床前检验到临床应用平稳过渡的试剂。

竞争情报和公司洞察，重点在于塑造生物成像试剂市场的策略性倡议、合作和产能投资。

生物成像试剂领域的公司层面发展趋势反映了专业创新与策略规模化之间的平衡。成熟的供应商致力于提升生产流程的严谨性、完善的监管文件以及广泛的模式相容性，以服务临床和机构客户。同时，小规模的专业公司则专注于新型化学技术、标靶探针和合作开发模式，以加速产品转换效用。在整体竞争格局中，试剂创新者、仪器製造商和临床研究机构之间的伙伴关係已成为检验新产品并展示其临床实际效用价值的常用机制。

为产业领导者提供加速创新、确保稳健供应链和优化成像试剂组合商业化的实用建议。

在技​​术变革和政策不确定性的背景下，行业领导者可以采取一些切实可行的措施来巩固自身地位。首先，他们应优先投资于供应链韧性建设，具体措施包括选择地域分散的供应商、实施严格的品管以及探索区域性生产模式，以减轻跨境中断的影响。这些措施将有助于提升业务永续营运，并巩固与临床和研究客户的长期合作关係。

透明的调查方法，概述了资料收集、相关人员参与和分析框架，以确保严谨性和可重复性。

为确保报告的可靠性和有效性，本报告的研究结合了与关键相关人员的直接对话、严谨的二手资料研究和交叉检验。对试剂研发人员、转化研究人员、临床使用者和采购负责人的结构化访谈是主要的资讯来源，旨在了解试剂选择、供应趋势和检验需求等方面的实际考量。基于这些定性见解，我们与化学、影像技术和法规事务领域的专家进行了有针对性的后续讨论和假设检验。

将策略重点、新兴机会和风险因素进行明确整合，以指导生物成像试剂策略的决策者。

总而言之，生物成像试剂处于材料科学、分子生物学和临床效用的关键交叉领域。探针化学和奈米材料领域的技术创新正在拓展各种成像模式的功能，而日益严格的监管要求和政策转变则凸显了稳健的生产和文件记录规范的重要性。那些积极提升价值链韧性、优先考虑转化检验并投资于模组化、可扩展试剂平台的公司，将更有利于在应用路径不断演变的过程中获取价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物成像试剂市场：依产品类型划分

  • 造影
    • 微气泡
    • 顺磁性试剂
    • 超顺磁性氧化铁
  • 萤光标记
    • 萤光蛋白
    • 奈米颗粒
    • 有机染料
  • 发光探针
    • 生物发光
    • 化学冷光
  • 量子点
    • 碳基
    • CdSe系列

第九章：依诊断成像方法分類的生物成像试剂市场

  • 电脑断层扫描
    • 碘造影剂
    • 奈米造影剂
  • 磁振造影
    • T1造影剂
    • T2造影剂
  • 光学成像
    • 生物发光成像
    • 萤光影像
  • 正子断层扫描
  • 单光子发射电脑断层扫描
    • 碘造影剂
    • Technetium造影剂

第十章：生物成像试剂市场：依最终用户划分

  • 学术研究机构
    • 研究机构
    • 大学
  • 合约研究机构
    • 临床医疗机构
    • 临床前服务供应商
  • 医院和诊断中心
    • 诊断中心
    • 医院
  • 製药和生物技术公司
    • 生技公司
    • 大型製药企业

第十一章：生物成像试剂市场：依应用领域划分

  • Exovivo 成像
    • 组织切片成像
    • 全器官成像
  • 体外成像
    • 显微镜检查
    • 盘式分析仪检测
  • 体内影像
    • 诊断影像
    • 治疗监测

第十二章：生物成像试剂市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：生物成像试剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：生物成像试剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国生物成像试剂市场

第十六章：中国生物成像试剂市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AAT Bioquest Inc
  • Agilent Technologies Inc
  • Bayer AG
  • Bio-Rad Laboratories Inc
  • Bio-Techne Corporation
  • Biotium Inc
  • Bracco Imaging SpA
  • Cardinal Health Inc
  • Cell Signaling Technology Inc
  • Curium Pharma SARL
  • Danaher Corporation
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies Inc
  • Guerbet SA
  • Lantheus Holdings Inc
  • Lumiprobe Corporation
  • Merck KGaA
  • New England Biolabs Inc
  • Promega Corporation
  • Revvity Inc
  • Roche Holding AG
  • Siemens Healthineers AG
  • Takara Bio Inc
  • Telix Pharmaceuticals Limited
  • Thermo Fisher Scientific Inc
Product Code: MRR-1A1A064C0515

The Biologic Imaging Reagents Market was valued at USD 16.73 billion in 2025 and is projected to grow to USD 18.09 billion in 2026, with a CAGR of 9.19%, reaching USD 30.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.73 billion
Estimated Year [2026] USD 18.09 billion
Forecast Year [2032] USD 30.98 billion
CAGR (%) 9.19%

Comprehensive introduction to biologic imaging reagents and their pivotal role in modern diagnostics and translational research across academic and clinical settings

Biologic imaging reagents have become an essential enabler of contemporary diagnostics, preclinical research, and translational science. These reagents span contrast agents used in computed tomography and magnetic resonance imaging, fluorescent labels and luminescent probes that illuminate molecular processes, and quantum dots that offer precise optical signatures. Collectively, they underpin a spectrum of applications from in vitro assay development and ex vivo tissue characterization to in vivo diagnostic imaging and therapeutic monitoring, serving researchers, clinicians, and industry developers alike.

The convergence of imaging hardware innovation, advanced molecular labeling chemistries, and data-driven image analysis has elevated the importance of reagent performance, reproducibility, and regulatory compliance. As stakeholders pursue higher sensitivity, specificity, and biocompatibility, reagent design increasingly reflects cross-disciplinary inputs spanning materials science, molecular biology, and clinical requirements. Consequently, procurement and development decisions hinge not only on immediate performance but also on considerations such as scalability, batch consistency, and downstream integration into workflows.

This introduction sets the stage for a deeper examination of how technological advances, policy shifts, and evolving end-user expectations are reshaping priorities for manufacturers, research institutions, and healthcare providers. The following sections explore these dynamics and their implications for innovation, sourcing, and strategic planning across the biologic imaging reagent ecosystem.

Analysis of transformative shifts reshaping the biologic imaging reagents landscape driven by technological convergence, regulatory evolution, and novel translational applications

The landscape for biologic imaging reagents is undergoing transformative shifts driven by the interplay of technology, regulation, and translational demand. On the technology front, advances in nanomaterials, protein engineering, and probe chemistry are enabling reagents that deliver higher signal-to-noise ratios, enhanced targeting specificity, and improved biostability. These capabilities are accelerating adoption in complex imaging modalities and opening new use cases in therapeutic monitoring and precision diagnostics.

Simultaneously, regulatory frameworks and quality expectations have moved toward greater transparency and lifecycle evidence. This has prompted suppliers to invest in manufacturing controls, characterization protocols, and documentation that support clinical translation. As a result, collaborative partnerships between reagent developers and clinical research organizations have become more strategic, enabling iterative validation and faster clinical-readiness of novel reagents.

Market participants are also adapting to shifts in research models and funding priorities that emphasize reproducibility and translational impact. End users increasingly select reagents not only for their analytical performance but also for supply reliability, regulatory traceability, and compatibility with multiparametric imaging workflows. In response, developers are prioritizing modular chemistries and scalable production processes that can be validated across preclinical and clinical stages. The combined effect of these dynamics is a more rigorous, innovation-driven ecosystem with clearer pathways from concept to clinical utility.

Assessing the cumulative impact of emerging United States tariff policies on supply chains, sourcing strategies, and commercial access for biologic imaging reagents

Emerging tariff policies instituted in the United States in 2025 have introduced a set of cumulative impacts that reverberate across sourcing, manufacturing, and procurement strategies for biologic imaging reagents. Many reagents rely on specialized raw materials, including rare elements, proprietary dyes, and nanoparticle precursors, which are often sourced internationally. Tariff-induced cost pressures therefore encourage companies to reassess supplier portfolios, increase inventory buffers, and explore strategic vertical integration to reduce exposure to cross-border price volatility.

Beyond direct cost effects, tariffs contribute to shifts in supply chain architecture. Organizations are evaluating nearshoring or regional manufacturing to shorten lead times and reduce customs complexity, while others are diversifying supplier networks to mitigate single-source risks. These adaptations can increase operational overhead in the near term but foster resilience that supports uninterrupted research and clinical operations over time. Procurement teams also face higher compliance and administrative burdens, as customs classifications and regulatory clearances become more central to onboarding new suppliers.

On the demand side, tighter purchasing budgets and extended procurement cycles influence product selection criteria, with stakeholders prioritizing reagents that offer multi-use flexibility and predictable availability. The cumulative result is a landscape where strategic sourcing, supplier qualification, and investment in local manufacturing capacity are increasingly essential considerations for companies seeking to preserve both margin and market access in a tariff-constrained environment.

In-depth segmentation insights highlighting product types, imaging modalities, end users, and application pathways that influence innovation and procurement decisions

A nuanced understanding of segmentation dynamics is central to strategic decision making in the biologic imaging reagents domain. When viewed by product type, the ecosystem includes contrast agents, fluorescent labels, luminescent probes, and quantum dots; within contrast agents, microbubbles, paramagnetic agents, and superparamagnetic iron oxide each address specific modality needs, while fluorescent labels span fluorescent proteins, nanoparticles, and organic dyes, and luminescent probes differentiate between bioluminescent and chemiluminescent approaches, with quantum dots split between carbon based and cadmium selenide based variants. Each product family carries distinct development trajectories, regulatory considerations, and application compatibilities that influence both R&D prioritization and commercial positioning.

Considering imaging modality segmentation, computed tomography, magnetic resonance imaging, optical imaging, positron emission tomography, and single photon emission computed tomography present varied reagent demands; computed tomography workstreams lean on iodinated and nanoparticle agents, magnetic resonance imaging relies on differentiated T1 and T2 agents, optical imaging encompasses bioluminescence and fluorescence imaging techniques, positron emission tomography frequently centers on FDG and related radiotracers, and single photon emission computed tomography continues to employ iodine and technetium agents. These modality-specific requirements shape formulation constraints, stability profiles, and safety testing pathways.

From the end-user perspective, academic and research institutes, contract research organizations, hospitals and diagnostic centers, and pharmaceutical and biotechnology companies each impose different expectations around reagent performance, supply continuity, and documentation; academic institutions often prioritize versatility and reproducibility, contract research organizations emphasize standardized deliverables for trial support, healthcare providers require regulatory-compliant products for clinical diagnostics, and industry developers seek scalable, GMP-compatible reagents for translational pipelines. Finally, application-based segmentation across ex vivo, in vitro, and in vivo imaging delineates different validation regimes, with ex vivo work including tissue section and whole organ imaging, in vitro covering microscopy and plate reader assays, and in vivo focusing on diagnostic imaging and therapeutic monitoring. Together, these intersecting segmentation lenses inform product development, go-to-market strategies, and partnership choices across the value chain.

Regional dynamics and strategic implications across the Americas, Europe Middle East and Africa, and Asia Pacific that are driving adoption and investment priorities

Regional dynamics shape both demand patterns and strategic priorities for biologic imaging reagents. In the Americas, strong clinical research infrastructure, established biotechnology clusters, and high investment in translational science drive demand for advanced reagents that support clinical trials and diagnostic innovation. Procurement cycles in this region emphasize regulatory traceability and long-term supplier relationships, and organizations often seek reagents that can smoothly transition from preclinical validation to clinical deployment.

In Europe, the Middle East and Africa region, diverse regulatory landscapes and varied healthcare system maturity create differentiated opportunities. In Western European markets, rigorous regulatory standards and consolidated healthcare purchasers favor suppliers with extensive documentation and quality systems, whereas markets across the Middle East and Africa may prioritize cost-effective, robust solutions and support for local capacity building. Cross-border collaborations and pan-regional clinical networks are increasingly important channels for reagent adoption and validation.

In the Asia Pacific region, rapid expansion of research capabilities, growing investment in biotechnology and imaging infrastructure, and a large base of clinical research activity create significant demand for both foundational reagents and innovative probes. Manufacturers and distributors targeting this region often tailor offerings to local logistical realities and regulatory pathways while pursuing partnerships to accelerate market entry. Across these regions, regional manufacturing, localized regulatory expertise, and distributor relationships play pivotal roles in how reagents are evaluated, procured, and integrated into research and clinical workflows.

Competitive intelligence and company insights focused on strategic moves, collaborative research, and capability investments shaping the biologic imaging reagents market

Company-level dynamics in the biologic imaging reagent space reflect a balance between specialized innovation and strategic scale. Established suppliers invest in manufacturing rigor, regulatory documentation, and broad modality compatibility to serve clinical and institutional customers, while smaller, specialist firms emphasize novel chemistries, targeted probes, and collaborative development models that accelerate translational relevance. Across the competitive landscape, partnerships between reagent innovators, instrument manufacturers, and clinical research providers are a common mechanism to validate new products and demonstrate real-world utility.

Investment in intellectual property around probe design, nanoparticle synthesis, and conjugation chemistry remains a differentiator, as does the ability to provide comprehensive technical support and application training. Companies that can pair reagent performance with reproducible protocols and strong customer support tend to secure longer-term adoption among research institutions and diagnostic centers. Additionally, strategic licensing and co-development agreements allow larger organizations to access cutting-edge innovations without internalizing full R&D costs, while allowing smaller innovators to scale manufacturing and distribution.

Mergers and acquisitions alongside selective alliances continue to shape capability footprints, enabling companies to offer integrated solutions across modalities and applications. For decision makers evaluating potential partners or acquisition targets, priority criteria include technical differentiation, regulatory readiness, manufacturing scalability, and a demonstrated track record of enabling reliable translational outcomes.

Actionable recommendations for industry leaders to accelerate innovation, secure resilient supply chains, and optimize commercialization of imaging reagent portfolios

Industry leaders can take several practical steps to strengthen their position amid technological change and policy uncertainty. First, prioritize investments in supply chain resilience by qualifying geographically diverse suppliers, implementing robust quality controls, and exploring regional manufacturing options to reduce exposure to cross-border disruptions. These measures improve continuity and support long-term relationships with clinical and research customers.

Second, commit resources to standardization and documentation practices that facilitate clinical translation, regulatory compliance, and interoperable workflows. Producing comprehensive characterization data, stability profiles, and validated protocols enhances customer confidence and accelerates adoption across end-user segments. Third, pursue collaborative partnerships with instrument manufacturers, clinical sites, and translational research centers to co-develop and validate reagents in real-world settings; these alliances de-risk product development and create compelling use cases for commercialization.

Fourth, align product portfolios with modality-specific requirements and end-user expectations by developing modular reagent platforms that can be tailored to computed tomography, magnetic resonance imaging, optical imaging, and nuclear modalities. Finally, emphasize talent and capability development in areas such as bioconjugation chemistry, nanomaterials, and regulatory affairs to maintain a competitive edge. By executing on these recommendations, organizations can enhance innovation velocity while managing operational and regulatory complexities.

Transparent research methodology outlining data collection, stakeholder engagement, and analytical frameworks used to ensure rigor and reproducibility

The research underpinning this report combines primary stakeholder engagement with rigorous secondary analysis and cross-validation to ensure reliability and relevance. Primary inputs included structured interviews with reagent developers, translational researchers, clinical users, and procurement professionals to capture practical considerations around reagent selection, supply dynamics, and validation needs. These qualitative insights informed targeted follow-up discussions and hypothesis testing with subject matter experts across chemistry, imaging modalities, and regulatory affairs.

Secondary sources encompassed peer-reviewed literature, regulatory guidance documents, technical specifications for imaging modalities, and company disclosures that describe product characteristics and strategic initiatives. Analytical frameworks were applied to synthesize this material, evaluate technology readiness, and map capability gaps across product classes and applications. Throughout the process, attention was paid to ensuring reproducibility via documented assumptions, traceable data sources, and methodological transparency.

Limitations are acknowledged where proprietary commercial data or emerging regulatory changes introduce uncertainty. To mitigate these, sensitivity checks and scenario-based reasoning were used to explore alternative outcomes and to highlight strategic inflection points. The overall methodology prioritizes triangulation of evidence and stakeholder validation to produce actionable insights that support informed decision making across development, procurement, and commercialization activities.

Conclusive synthesis of strategic priorities, emerging opportunities, and risk considerations to guide decision makers in biologic imaging reagent strategies

In synthesis, biologic imaging reagents occupy a critical intersection of materials science, molecular biology, and clinical utility. Technological innovations in probe chemistry and nanomaterials are expanding capabilities across imaging modalities, while heightened regulatory expectations and policy shifts underscore the need for robust manufacturing and documentation practices. Companies that proactively address supply chain resilience, prioritize translational validation, and invest in modular, scalable reagent platforms will be better positioned to capture value as adoption pathways evolve.

Emerging challenges such as tariff-driven supply disruptions and increasing demand for clinical-grade evidence necessitate a strategic combination of operational agility and scientific excellence. Decision makers should weigh investments in local manufacturing, strategic partnerships, and regulatory expertise against the benefits of rapid innovation and market access. By focusing on reproducibility, interoperability with imaging systems, and proven clinical utility, organizations can differentiate their offerings and foster trust among researchers and clinicians.

This conclusion reinforces the central thesis that integrated strategies - spanning product design, supply chain management, and collaborative validation - will determine which organizations succeed in translating reagent innovation into sustained clinical and research impact. The subsequent call to action outlines how interested stakeholders can acquire the full research report and pursue tailored engagements to operationalize these findings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologic Imaging Reagents Market, by Product Type

  • 8.1. Contrast Agents
    • 8.1.1. Microbubbles
    • 8.1.2. Paramagnetic Agents
    • 8.1.3. Superparamagnetic Iron Oxide
  • 8.2. Fluorescent Labels
    • 8.2.1. Fluorescent Proteins
    • 8.2.2. Nanoparticles
    • 8.2.3. Organic Dyes
  • 8.3. Luminescent Probes
    • 8.3.1. Bioluminescent
    • 8.3.2. Chemiluminescent
  • 8.4. Quantum Dots
    • 8.4.1. Carbon Based
    • 8.4.2. CdSe Based

9. Biologic Imaging Reagents Market, by Imaging Modality

  • 9.1. Computed Tomography
    • 9.1.1. Iodinated Agents
    • 9.1.2. Nanoparticle Agents
  • 9.2. Magnetic Resonance Imaging
    • 9.2.1. T1 Agents
    • 9.2.2. T2 Agents
  • 9.3. Optical Imaging
    • 9.3.1. Bioluminescence Imaging
    • 9.3.2. Fluorescence Imaging
  • 9.4. Positron Emission Tomography
  • 9.5. Single Photon Emission Computed Tomography
    • 9.5.1. Iodine Agents
    • 9.5.2. Technetium Agents

10. Biologic Imaging Reagents Market, by End User

  • 10.1. Academic And Research Institutes
    • 10.1.1. Research Institutes
    • 10.1.2. Universities
  • 10.2. Contract Research Organizations
    • 10.2.1. Clinical Providers
    • 10.2.2. Preclinical Providers
  • 10.3. Hospitals And Diagnostic Centers
    • 10.3.1. Diagnostic Centers
    • 10.3.2. Hospitals
  • 10.4. Pharmaceutical And Biotechnology Companies
    • 10.4.1. Biotechnology Companies
    • 10.4.2. Large Pharmaceutical Companies

11. Biologic Imaging Reagents Market, by Application

  • 11.1. Ex Vivo Imaging
    • 11.1.1. Tissue Section Imaging
    • 11.1.2. Whole Organ Imaging
  • 11.2. In Vitro Imaging
    • 11.2.1. Microscopy
    • 11.2.2. Plate Reader Assays
  • 11.3. In Vivo Imaging
    • 11.3.1. Diagnostic Imaging
    • 11.3.2. Therapeutic Monitoring

12. Biologic Imaging Reagents Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Biologic Imaging Reagents Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biologic Imaging Reagents Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Biologic Imaging Reagents Market

16. China Biologic Imaging Reagents Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AAT Bioquest Inc
  • 17.6. Agilent Technologies Inc
  • 17.7. Bayer AG
  • 17.8. Bio-Rad Laboratories Inc
  • 17.9. Bio-Techne Corporation
  • 17.10. Biotium Inc
  • 17.11. Bracco Imaging S.p.A.
  • 17.12. Cardinal Health Inc
  • 17.13. Cell Signaling Technology Inc
  • 17.14. Curium Pharma SARL
  • 17.15. Danaher Corporation
  • 17.16. FUJIFILM Holdings Corporation
  • 17.17. GE HealthCare Technologies Inc
  • 17.18. Guerbet S.A.
  • 17.19. Lantheus Holdings Inc
  • 17.20. Lumiprobe Corporation
  • 17.21. Merck KGaA
  • 17.22. New England Biolabs Inc
  • 17.23. Promega Corporation
  • 17.24. Revvity Inc
  • 17.25. Roche Holding AG
  • 17.26. Siemens Healthineers AG
  • 17.27. Takara Bio Inc
  • 17.28. Telix Pharmaceuticals Limited
  • 17.29. Thermo Fisher Scientific Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IMAGING MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIOLOGIC IMAGING REAGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIOLOGIC IMAGING REAGENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MICROBUBBLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MICROBUBBLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MICROBUBBLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PARAMAGNETIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PARAMAGNETIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PARAMAGNETIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SUPERPARAMAGNETIC IRON OXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SUPERPARAMAGNETIC IRON OXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SUPERPARAMAGNETIC IRON OXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ORGANIC DYES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ORGANIC DYES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ORGANIC DYES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY BIOLUMINESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY BIOLUMINESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY BIOLUMINESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CHEMILUMINESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CHEMILUMINESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CHEMILUMINESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CARBON BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CARBON BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CARBON BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CDSE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CDSE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CDSE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IODINATED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IODINATED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IODINATED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY NANOPARTICLE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY NANOPARTICLE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY NANOPARTICLE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY T1 AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY T1 AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY T1 AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY T2 AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY T2 AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY T2 AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IODINE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IODINE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IODINE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY TECHNETIUM AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY TECHNETIUM AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY TECHNETIUM AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CLINICAL PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CLINICAL PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CLINICAL PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRECLINICAL PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRECLINICAL PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRECLINICAL PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY TISSUE SECTION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY TISSUE SECTION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY TISSUE SECTION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY WHOLE ORGAN IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY WHOLE ORGAN IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY WHOLE ORGAN IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PLATE READER ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PLATE READER ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PLATE READER ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY FLUORESCENT LABELS, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY LUMINESCENT PROBES, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY QUANTUM DOTS, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY EX VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VITRO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY IN VIVO IMAGING, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA BIOLOGIC IMAGING REAGENTS MARKET SIZE, BY F